New study explores how to reverse common blood thinners
NCT ID NCT07312851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a drug called andexanet alfa, which is designed to reverse the effects of common blood thinners like rivaroxaban and apixaban. Researchers will give these blood thinners to 179 healthy volunteers, then give andexanet to see how well it works and how it interacts with another blood thinner, enoxaparin. The goal is to learn more about dosing and timing, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
andexanet alfa
What this could lead to
If successful, this could help doctors better understand how to reverse the effects of certain blood thinners in emergencies.
What could go wrong
This is a very early Phase 1 study in healthy volunteers, not patients. It only measures lab effects, not real-world outcomes, and may not translate to clinical use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Berlin, 14050, Germany
-
Research Site
Harrow, HA1 3UJ, United Kingdom